Varicella Zoster Infection Treatment Market Set to Reach USD 2.05 billion by 2028 at a 4.1% of CAGR

Varicella Zoster Infection Treatment Market

The global Varicella Zoster Infection Treatment Market, valued at over USD 1.5 billion in 2020, is projected to grow significantly, reaching USD 2.0 billion by 2028. According to projections by Future Market Insights, the market is expected to experience a steady growth rate with a compound annual growth rate (CAGR) of 4.1%. This growth is largely driven by the increasing incidence of Varicella Zoster Virus (VZV)-related infections, including chickenpox and herpes zoster (shingles), which are affecting an expanding demographic, including children and the elderly.

Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d36343636

Acyclovir, a commonly prescribed antiviral medication for the treatment of varicella zoster infections, currently holds a substantial share of over 55.7% in the market. As the primary treatment for VZV-related infections, acyclovir continues to play a dominant role in managing both chickenpox and shingles. The growing demand for effective treatments and the increasing awareness of the risks associated with VZV infections are propelling the market forward.

The rise in shingles cases, particularly among older adults and an increasing number of pediatric cases, is a key factor contributing to the market’s growth. Shingles, which is a painful reactivation of the VZV infection, has become more prevalent in both children and the elderly. As the demand for effective treatments rises, healthcare providers are looking to expand treatment options, which further fuels market expansion.

Key Takeaways:

1. The Varicella Zoster Infection Treatment Market is expected to grow from USD 1.5 billion in 2020 to USD 2.0 billion by 2028, with a CAGR of 4.1%.
2. Acyclovir dominates the market, holding a 55.7% share in the treatment of varicella zoster infections.
3. The increasing incidence of herpes zoster (shingles) among children and the elderly is driving market demand for effective treatments.
4. Rising awareness and demand for treatment options are key factors contributing to the market’s growth trajectory.

Key Point:

• The varicella-zoster virus, also known as human herpesvirus 3, causes chickenpox and shingles.

• The market is driven by the rising incidence of herpes zoster among children and the elderly, as well as the increasing demand for treatment1. The market is also growing because of advances in technology and a better understanding of viral latency and reactivation.

• The increasing demand for vaccination in many countries is expected to boost the demand for the varicella treatment market in the coming years.

• The antiviral drug segment is expected to hold a significant market share because these drugs reduce viral shedding and accelerate the resolution of symptoms. Acyclovir and valacyclovir are common antiviral treatments.

Full Report Revealed – https://www.futuremarketinsights.com/reports/varicella-zoster-infection-treatment-market

Key Companies Profiled

Novartis AG; Pfizer Inc.; Abbott Laboratories; Sun Pharmaceuticals Industries Ltd.; Valeant Pharmaceuticals International Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy’s Laboratories, ltd.; Mylan N.V. and; GlaxoSmithKline

Varicella Zoster Infection Treatment – Market Segmentation – by Category

By Drug Type:

• Acyclovir
• Valacyclovir
• Famciclovir

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores

Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• APECJ
• China
• Japan
• Middle East Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube